CUV recruits 200 patients in Phase III vitiligo trial CUV105
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The trial aims to assess the efficacy of SCENESSE® in achieving significant repigmentation in patients with darker skin types. Clinical observations from the trial have shown positive outcomes, with patients reporting satisfaction and well-tolerated treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL renews share buy-back program
- Positive preliminary results for PRENUMBRA Instant in stroke
- Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025
- Half Year Results Announcement
- Preliminary results from SCENESSE adolescent EPP study
Later from Clinuvel Pharmaceuticals
- CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
- CLINUVEL management update
- Study confirms NB-UVB needed to activate repigmentation
- CLINUVEL preparing upgrade of ADR program, NASDAQ uplist
- CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals